首页> 美国卫生研究院文献>The EPMA Journal >Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: Progress overview beyond predictive and personalized diagnosis
【2h】

Non-invasive prenatal diagnosis using cell-free fetal nucleic acids in maternal plasma: Progress overview beyond predictive and personalized diagnosis

机译:在母体血浆中使用无细胞胎儿核酸的非侵入性产前诊断:超越预测和个性化诊断的进展概述

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The discovery of circulating cell-free fetal DNA (cffDNA) in maternal plasma allowed for the development of alternative methodologies that may facilitate safe non-invasive prenatal diagnosis (NIPD). The low concentration of cffDNA in maternal plasma, however, and the coexistence of maternal DNA limit its clinical application to the detection or exclusion of fetal targets that are not present in the mother, such as Y chromosome sequences, the RHD gene in a RhD-negative woman and genetic conditions inherited from the father. Strategies for NIPD of monogenic disorders and fetal chromosomal aneuploidies have also been achieved using next-generation sequencing and could be introduced to the clinics as soon as cost-effective and high throughput protocols are developed.
机译:母体血浆中循环性无细胞胎儿DNA(cffDNA)的发现允许开发其他方法,这些方法可以促进安全的非侵入性产前诊断(NIPD)。然而,母体血浆中低浓度的cffDNA和母体DNA的共存将其临床应用限制于检测或排除母体中不存在的胎儿靶标,例如Y染色体序列,RhD-负面的女人和遗传条件是从父亲那里继承下来的。单基因疾病和胎儿染色体非整倍性的NIPD策略也已通过下一代测序得以实现,一旦开发出具有成本效益和高通量的方案,便可以将其引入临床。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号